Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01811992
Recruitment Status : Completed
First Posted : March 15, 2013
Last Update Posted : August 31, 2021
Sponsor:
Collaborator:
Phase One Foundation
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Tracking Information
First Submitted Date  ICMJE February 13, 2013
First Posted Date  ICMJE March 15, 2013
Last Update Posted Date August 31, 2021
Actual Study Start Date  ICMJE April 2014
Actual Primary Completion Date February 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 25, 2021)
Maximum Tolerated Dose (MTD) [ Time Frame: 21 days post administration of study vectors ]
Vectors AdhCMV- TK and Ad-hCMV-Flt3L were administered at time of surgery and the MTD determined by dose-limiting toxicities. Toxicities assessed and graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.
Original Primary Outcome Measures  ICMJE
 (submitted: March 12, 2013)
Dose-Limiting Toxicity [ Time Frame: 24 months ]
  • Grade 4 toxicity for constitutional symptoms as graded by the NCI Common Terminology Criteria for Adverse Events v4.03 (CTCAE) with the exception of fever >40°C for ≤24 hours.
  • Grade 3 or greater CTCAE v4.03 neurologic toxicity relative to the changes from the pre-treatment neurological status and attributable to the study therapy regimen.
  • Grade 3 or greater non hematologic toxicity as defined by CTCAE v.4.03, and attributable to the study therapy regimen.
  • Grade 2 or greater autoimmune events as defined by CTCAE v.4.03
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 20, 2016)
Number of Patients Alive at 12 and 24 Months [ Time Frame: 24 Months ]
To assess in a preliminary fashion the potential benefit of AdhCMV- TK and Ad-hCMV-Flt3L treatment of primary malignant gliomas by assessing overall survival (OS) at 12 and 24 months.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 12, 2013)
  • Functional Status - Karnofsky Performance Status, Glasgow Coma Scale [ Time Frame: Pre-operative to three days post-operative ]
  • Medical and Neurological Examinations - Hematology, Clinical Chemistry, Physical Exam, Neurological Assessment, Adenoviral antibodies [ Time Frame: 24 Month ]
  • MRI [ Time Frame: Within 48 hours post-operative ]
    To determine the degree of tumor resection
  • Survival from Date of Operation [ Time Frame: 24 Month ]
  • Progression-free survival [ Time Frame: 24 Month ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma
Official Title  ICMJE A Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-Stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma
Brief Summary Despite the marginal improvements in survival of patients suffering from malignant glioma treated with gene therapy vectors, the clinical trials conducted so far using viral vectors, in particular adenoviral vectors, have proven that the use of adenoviral vectors is a safe therapeutic approach, even in large, multicenter, phase 3 clinical trials. Treatment of malignant glioma using gene transfer modalities typically consists of surgical debulking of the tumor mass followed by the administration of the viral vectors into the brain tissue surrounding the tumor cavity. This study will combine direct tumor cell killing (TK) and immune-mediated stimulatory (Flt3L) gene transfer approaches delivered by first generation adenoviral vectors.
Detailed Description This is a Phase 1, multiple center open label, dose escalation safety study of Ad-hCMV-TK and Ad-hCMV-Flt3L delivered to the peritumoral region after tumor resection. This study will combine direct tumor cell killing (TK) and immune-mediated stimulatory (Flt3L) gene transfer approaches delivered by first generation adenoviral vectors. Treatment with HSV1-TK is expected to kill transduced brain cells, thus exposing tumor antigen. Treatment with Flt3L, a cytokine known to cause proliferation of dendritic cells, should cause the migration of dendritic cells to the peritumoral brain and remaining tumor. There, they will be exposed to tumor antigens released from dying glioma cells through TK + valacyclovir-induced glioma cell death, and thus mediate a specific anti-malignant glioma immune response against remaining malignant glioma cells.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Malignant Glioma
  • Glioblastoma Multiforme
Intervention  ICMJE Biological: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L

Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.

Radiation and chemotherapy will be administered as per standard of care.

Study Arms  ICMJE Experimental: Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L

This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:

  • A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp
  • B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp
  • C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp
  • D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp
  • E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp
  • F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp

Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation.

Intervention: Biological: Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Publications * Lowenstein PR, Castro MG. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Clin Immunol. 2018 Apr;189:43-51. doi: 10.1016/j.clim.2017.07.006. Epub 2017 Jul 15. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 9, 2019)
19
Original Estimated Enrollment  ICMJE
 (submitted: March 12, 2013)
18
Actual Study Completion Date  ICMJE January 2021
Actual Primary Completion Date February 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Newly diagnosed supratentorial brain lesion compatible with a high grade glioma by MR (magnetic resonance) with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR).Intraoperative histological frozen section at the time of tumor resection should be compatible with high-grade glioma. If intraoperative diagnosis is not high grade glioma, the patient will not be enrolled. "High grade glioma" can include:Glioblastoma multiforme (WHO grade IV); Anaplastic astrocytoma (WHO grade III); Anaplastic oligodendroglioma (WHO grade III); and Anaplastic ependymoma (WHO grade III).
  • Karnofsky score ≥70 (Karnofsky scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 100 where 100 represents perfect health and 0 represents death)
  • CBC (complete blood count)/differential obtained within 14 days prior, with adequate bone marrow function defined as follows:
  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3;
  • Platelets ≥ 100,000 cells/mm3;
  • Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥10.0 g/dl is acceptable.);
  • Adequate renal function, as defined below:
  • BUN (blood urea nitrogen) ≤ 30 mg/dl within 14 days prior.
  • Creatinine ≤ 1.7 mg/dl within 14 days prior.
  • Adequate hepatic function, as defined below:
  • Bilirubin ≤ 2.0 mg/dl within 14 days prior.
  • ALT (alanine aminotransferase)/AST (aspartate aminotransferase) ≤ 3x laboratory upper limit of normal within 14 days prior.
  • Male and female; both genders must use contraception if of reproductive capacity
  • Capable of informed consent
  • 18-75 years of age
  • For women of child bearing age, a negative pregnancy test performed within 14 days of surgery

Exclusion Criteria:

  • Diffusely multifocal lesion that is not amenable to GTR (gross total resection)
  • Tumors infiltrating the cerebellum, bilateral corpus callosum ("butterfly glioma"), ventricular system, or brain stem
  • Infratentorial high grade glioma
  • Primary central nervous system (CNS) disease that would interfere with subject evaluation
  • Current diagnosis of other cancer except curative cervical cancer in situ, basal or squamous cell carcinoma of the skin.
  • Evidence of other significant disease including hematologic, renal or liver disease that is not explained by the patient's current medical condition or concomitant disease, (i.e. levels of absolute neutrophil count (ANC), hemoglobin, platelets, clotting time, serum creatinine, etc). Final decision on inclusion will be made by physician, concerning suitability of patient for surgery.
  • HIV, Hepatitis B, Hepatitis
  • Active systemic infection
  • Immunosuppressive disorders (chronic steroid therapy, acquired or congenital immune deficiency syndromes, autoimmune disease)
  • Serious medical conditions (CHF (congestive heart failure), angina, diabetes mellitus, Chronic obstructive pulmonary disease, abnormal bleeding diathesis)
  • Any contraindication for undergoing MRI (magnetic resonance imaging)
  • Pregnant or lactating females
  • Unacceptable anesthesia risk
  • Evidence of bleeding diathesis or use of anticoagulant medication or any medication that may increase the risk of bleeding that cannot be stopped prior to surgery.
  • Prior gene therapy
  • Allergy to valacyclovir or unable to take oral tablets
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01811992
Other Study ID Numbers  ICMJE UMCC 2015.024
HUM00057130 ( Other Identifier: University of Michigan )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Michigan Rogel Cancer Center
Study Sponsor  ICMJE University of Michigan Rogel Cancer Center
Collaborators  ICMJE Phase One Foundation
Investigators  ICMJE
Principal Investigator: Pedro Lowenstein, MD, PhD University of Michigan
PRS Account University of Michigan Rogel Cancer Center
Verification Date August 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP